Description
Taylor & Francis Heart Failure in Clinical Practice 2000 Edition by John GF Cleland, John JV McMurray
Following the success of the first edition and the great number of advances taking place in the diagnosis, management and treatment of heart failure, an up-to-date second edition has become necessary. The editors have added several new chapters and new contributors to the new edition. Heart failure is rapidly becoming the biggest cardiovascular disorder in the industrialized countries. With the development of new drugs for heart failure, such as ACE inhibitors, the prognosis for the presenting patient improves. The editors have brought together a team of international experts to give their views of the new developments in the diverse areas in heart failure. Table of contents : - I Epidemiology, causes and consequences of coronary heart failure: 1. Epidemiology of heart failure: what does the future hold? 2. Hypertension as a cause of heart failure - is it still important? 3. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? 4. Isolated diastolic dysfunction - is it really a cause of symptomatic heart failure? II Pathophysiology: The ABC of the natriuretic peptides in heart failure: 5. pathophysiology, diagnostic and therapeutic potential 6. Endothelin in the pathophysiology of chronic heart failure 7. Aldosterone in chronic heart failure: have we forgotten it? 8. Adrenomedullin in heart failure: biochemical curiosity or pathophysiological player? 9. Cardiomyocyte apoptosis: a cause of heart failure progression 10. Cardiac interstitium in heart failure: more important than muscle? 11. The blood vessels in heart failure: vascular failure also? 12. Skeletal muscle and metabolism in heart failure: major or minor player? 13. The future is molecular? The molecular biology of heart failure III Treatment: 14. What's new with ACE inhibitors? 15. Angiotensin II receptor antagonists: the end of ACE inhibitors? 16. New data available on angiotensin II receptor antagonists 17. Digoxin: a requiem? 18. Beta-blockers in heart failure: help, hope or hype? 19. Arrhythmias and sudden death in heart failure: is there light on the horizon? 20. New trials and CHF statistics: EMIAT, CAMIAT, SWORD, ICD trials 21. Calcium channel blockers in heart failure: has the bridge been crossed? 22. Surgery: does it have anything to offer in heart failure? 23. Non-pharmacological treatment of heart failure: just as important? 24. Quality of life